CD9 and cancer: Noteworthy, at a lower concentration such as 10 μM, the tested derivatives have significantly decreased the percentage of viable cancer cells: for BA1, it was 19.6%, for BA2 it was 18.7%, for BA3 it was 13.6%, and for BA4 it was 32.3%.